Inicio・Lista de Acciones・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Cerrado

SectorSanidad

26.4 0.34

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

26.1

Máximo

26.54

Métricas clave
By Trading Economics
Ingresos	93M -92M
Ventas	78M 214M
BPA	-0.9
Margen de beneficios	-42.991
Empleados	1,371
EBITDA	94M -61M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+92.26% upside

Dividendos
By Acuity
Próximas Ganancias	3 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	178M 2.6B
Apertura anterior	26.06
Cierre anterior	26.4

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

61 / 340 Clasificación en Healthcare

Ultragenyx Pharmaceutical Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 ago 2026, 00:06 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, reaching a high of 2.96% following Friday's close amid broader economic concerns.

14 ago 2026, 22:51 UTC

Ultragenyx Pharmaceutical Inc shares rose in after-market trading, advancing significantly since Friday's close amid easing expectations for Federal Reserve interest rate hikes.

13 ago 2026, 19:16 UTC

Correlated Moves

Ultragenyx Pharmaceutical Inc. is declining, reflecting broader biotech sector weakness and a noted correlation with LABU's significant downturn.

12 ago 2026, 22:16 UTC

Ultragenyx Pharmaceutical shares are higher in after-market trading, reflecting positive price movement amid a stable monetary policy outlook and recent inflation data.

11 ago 2026, 19:36 UTC

News

Ultragenyx Pharmaceutical reached a settlement with Esjay Pharma over DOJOLVI patent litigation, allowing a generic version to launch in 2023. Shares are higher today.

10 ago 2026, 19:16 UTC

News

HC Wainwright reiterated its Buy rating on Ultragenyx Pharmaceutical, maintaining a $50 price target, contributing to shares trading higher during the session.

7 ago 2026, 20:03 UTC

News

Ultragenyx Pharmaceutical reported a loss of -$0.90 per share, beating estimates. Revenue of $214 million also exceeded expectations, but shares are trading roughly flat.

6 ago 2026, 23:21 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, showing unusual strength despite remaining below their 20-day moving average.

5 ago 2026, 19:52 UTC

News

Ultragenyx shares are lower after Wells Fargo cut its price target to $45. The company reported an EPS loss of $0.90, exceeding expectations.

4 ago 2026, 23:02 UTC

News

Ultragenyx Pharmaceutical reported second-quarter revenue of $214 million and narrowed its net loss to $92 million, with shares trading higher in after-market hours.

3 ago 2026, 22:51 UTC

Ultragenyx Pharmaceutical shares are trading roughly flat after-market. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

31 jul 2026, 19:52 UTC

Correlated Moves

Ultragenyx Pharmaceutical is lower today amid a decline in the Biotechnology sub-sector, with shares near the lower end of their one-month range.

30 jul 2026, 19:58 UTC

Correlated Moves

Ultragenyx rises, supported by SPDR S&P Biotech ETF gains.

29 jul 2026, 18:43 UTC

Ultragenyx Pharmaceutical is lower today, continuing a decline amid broader market pressures from rising crude oil prices and geopolitical tensions.

28 jul 2026, 19:03 UTC

Ultragenyx Pharmaceutical Inc shares are trading lower, reflecting a challenging performance backdrop amid strength in U.S. mega-cap stocks. No specific news was identified.

27 jul 2026, 19:07 UTC

Ultragenyx Pharmaceutical Inc shares are higher as crude oil prices decline, easing geopolitical concerns. No specific company news was identified for the move.

24 jul 2026, 19:51 UTC

Ultragenyx Pharmaceutical Inc shares are declining, continuing a trend of lower daily closes. Broader market volatility and new tariffs may be contributing factors.

22 jul 2026, 19:36 UTC

Ultragenyx Pharmaceutical shares are declining amid rising crude oil prices due to U.S.-Iran tensions. The stock remains below its 20-day moving average.

21 jul 2026, 19:22 UTC

Correlated Moves

Rising amid broader market gains and SPDR S&P Biotech support.

20 jul 2026, 19:17 UTC

Correlated Moves

Ultragenyx Pharmaceutical is declining amid a broader downturn in the Biotechnology sector, continuing a trend of seven consecutive lower sessions.

Comparación entre iguales

Cambio de precio

Ultragenyx Pharmaceutical Inc previsión

Precio Objetivo

By TipRanks

92.26% repunte

Estimación a 12 Meses

Media 50.93 USD 92.26%

Máximo 96 USD

Mínimo 27 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ultragenyx Pharmaceutical Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

Comprar

Mantener

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para Ultragenyx Pharmaceutical Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

61 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.